Navigation Links
Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
Date:6/22/2013

RIDGEFIELD, Conn. and INDIANAPOLIS, June 22, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced two late-breaking presentations with results from a pooled analysis of four pivotal phase III trials of the investigational agent empagliflozin* in people with type 2 diabetes (T2D).

In the pooled analysis, presented at the American Diabetes Association 73rd Scientific Sessions®, people with T2D treated with empagliflozin versus placebo achieved significant reductions in HbA1c, fasting plasma glucose (FPG), weight and blood pressure after 24 weeks.1 In the same analysis, people treated with empagliflozin vs. placebo experienced an increased frequency of genital infections, but not urinary tract infections (UTIs).2

Empagliflozin is a member of the sodium glucose co-transporter-2 (SGLT2) inhibitor class of compounds, and is being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption by the kidney.

"We are primarily encouraged by the blood sugar lowering results seen in this analysis," said Christophe Arbet-Engels, PhD, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "People with type 2 diabetes face different challenges. Many of them are not meeting their blood sugar level goals and have difficulties managing other factors such as weight and increased blood pressure."

About Posters #69-LB and #74-LB
Both posters are based on pooled data from 2,477 people with T2D who participated in one of four randomized, placebo-controlled phase III trials that investigated empagl
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
2. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
3. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
4. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
5. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
6. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
7. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
8. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
9. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
10. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
11. Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... MEXICO CITY , July 25, 2014 ... a Latin American healthcare sciences publisher, launched a library ... on conditions such as cancer and heart disease. Healthcare ... most up-to-date information to deliver better patient care. ... rapidly, with many relying on smartphones and tablets to ...
(Date:7/25/2014)... Inc. (NASDAQ: IDXX ) today reported that ... versus the prior year period to $390 million. Organic ... 2014 versus the prior year period was 9%, or ... Earnings per diluted share ("EPS") for the quarter ended ... period to $1.10."In the second quarter, we continued to ...
(Date:7/25/2014)... , July 25, 2014  Semler Scientific, Inc. ... medical risk assessment company that develops patented products ... evaluating chronic diseases, today reported financial results for ... 30, 2014. "The second quarter ... said Doug Murphy-Chutorian , M.D., chief executive ...
Breaking Medicine Technology:Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 3Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 4IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23IDEXX Laboratories Announces Second Quarter Results 24IDEXX Laboratories Announces Second Quarter Results 25IDEXX Laboratories Announces Second Quarter Results 26IDEXX Laboratories Announces Second Quarter Results 27IDEXX Laboratories Announces Second Quarter Results 28IDEXX Laboratories Announces Second Quarter Results 29IDEXX Laboratories Announces Second Quarter Results 30IDEXX Laboratories Announces Second Quarter Results 31IDEXX Laboratories Announces Second Quarter Results 32IDEXX Laboratories Announces Second Quarter Results 33
... at High,Risk , ,WASHINGTON, March 9, 2007 ... history of end-stage renal disease (ESRD), and,these individuals appear ... reports a study in the April Journal of,the American ... disease is more frequent in,African-Americans, who are also at ...
... Pharmaceuticals,Inc. (OTCBB:CGXP), a biopharmaceutical company focused on,infectious ... catheter,treated with a Ceragenin compound demonstrated virtually ... In the study, polyurethane catheters treated with ... along with an,untreated catheter. At day 21, ...
Cached Medicine Technology:Nearly 1 in 10 Americans Has A Relative With Kidney Failure 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3
(Date:7/26/2014)... 2014 According to the Metabolic Enhancement ... a comprehensive bodybuilding program that helps men lose body ... steroids . The program also instructs men how to ... , Vkool reveals in its review that this program ... help men get ripped and jacked at the same ...
(Date:7/25/2014)... July 26, 2014 Dental Perfection, a ... dental services including general dentistry, clear braces and much ... September this year in Derby. The new practice, which ... HollyBrook Medical Centre in Littleover, Derby. Patients may already ... , The new dental practice, which is headed by ...
(Date:7/25/2014)... (PRWEB) July 26, 2014 According ... Monitoring Market by Product (vibration monitoring, thermography, ultrasound ... signature analysis), Component, Application and Geography - Global ... the machine health monitoring market is expected to ... 2014 to 2020. , Browse 117 market data ...
(Date:7/25/2014)... Ticket Down announces that they ... Guinness International Champions Cup match between international soccer powerhouses ... on Sunday, July 27th. This well-known ticket ... SOCCER-2014 for added savings. , 2014 is turning out ... in North America. Countless international soccer teams have been ...
(Date:7/25/2014)... USA (PRWEB) July 25, 2014 As reported ... Use, OD Deaths Increase (7/20), Michigan has seen a nearly ... four years. While the count was 271 between 1999 and ... range. DEA Agents believe that, like other states, drug users ... the drug via prescription pills. He compared the price of ...
Breaking Medicine News(10 mins):Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 2Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 3Health News:Derby Cosmetic Dentist Dental Perfection to Open New Practice in Littleover, Derby this September 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Liverpool FC vs. Olympiacos FC Tickets Soldier Field: Ticket Down Slashes Ticket Prices for Guinness International Champions Cup in Chicago on Sunday, July 27th 2Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2
... ... concern of hospitals is keeping their patients safe while within their facility. To ... identifiers to patients that may present a higher risk of falling while in ... for a variety of reasons, have a higher than normal risk of being ...
... ... survivor and inspirational comedian, Hugh Chatfield, to host “Inspiration for Injured Service Members ... by nationally-recognized and sought-after comedian, Bob Marley, and USMC Vet, funnyman George Hamm. ... ...
... , HOUSTON , Jan. 14 ... was named the 2009 Marathon Oil Corporation Paul "Bear" Bryant Coach ... a coach has received the award twice. , Petersen was ... at an awards dinner Thursday evening in Houston , which ...
... , , Twenty-one ... , Jan. 14 More than 300 regulatory professionals ... most recent exam period for the professional certification. Candidates for the ... in autumn of 2009, with 315 achieving a passing score. Twenty-one ...
... RESEDA, Calif. , Jan. 14 ... Jewish Home in Reseda, CA , has been selected ... its Delegate to AAHSA, the American Association of Homes and ... membership at the AAHSA House of Delegates. , (Photo: ...
... , , LOS ANGELES , ... and Gibson, Dunn & Crutcher LLP filed a class ... children with autism against the Eastern Los Angeles Regional ... for their condition.  ELARC, a nonprofit agency through which ...
Cached Medicine News:Health News:Midbrook Assists Local Hospital with Fall Kit Production 2Health News:Midbrook Assists Local Hospital with Fall Kit Production 3Health News:Inspirational Comedy Night to Give Hope and Laughter to Iraq/Afghanistan Injured Veterans and Service Members 2Health News:Boise State's Chris Petersen Becomes First Repeat Winner of the Paul 'Bear' Bryant Coach of the Year Award 2Health News:More Than 300 Earn Regulatory Affairs Certification (RAC), the Only Professional Certification for the Healthcare Product Regulatory Field 2Health News:More Than 300 Earn Regulatory Affairs Certification (RAC), the Only Professional Certification for the Healthcare Product Regulatory Field 3Health News:Molly Forrest, CEO-President of the Los Angeles Jewish Home, Elected to Aging Services of California Board of Directors 2Health News:Molly Forrest, CEO-President of the Los Angeles Jewish Home, Elected to Aging Services of California Board of Directors 3Health News:Molly Forrest, CEO-President of the Los Angeles Jewish Home, Elected to Aging Services of California Board of Directors 4Health News:Class Action Suit Filed to Defend Rights of Children With Autism to Vital, Cost-Saving Treatment 2Health News:Class Action Suit Filed to Defend Rights of Children With Autism to Vital, Cost-Saving Treatment 3
Substrate Plasma for Factor IX Assay by STA© Analyzers. Freeze-dried human plasma from which factor IX has been removed by selective immuno-adsorption....
Enzyme Immunoassay of von Willebrand Factor Antigenby ELISA Method, 96 tests....
Enzyme Immunoassay of Factor IX Antigen by ELISA Method, 96 tests....
Enzyme Immunoassay of Platelet Factor 4 Antigen by ELISA Method, 96 tests....
Medicine Products: